Browsing Radiotherapy and Imaging by author "Melcher, Alan"
Now showing items 41-53 of 53
-
Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller, LME; Holmes, M; Michael, JL; Scott, GB; West, EJ; et al. (BMJ PUBLISHING GROUP, 2019-07-01)BACKGROUND: The oncolytic virus, coxsackievirus A21 (CVA21), has shown promise as a single agent in several clinical trials and is now being tested in combination with immune checkpoint blockade. Combination therapies offer ... -
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings, VA; Scott, GB; Rose, AMS; Scott, KJ; Migneco, G; et al. (CELL PRESS, 2019-06-05)A clinical oncolytic herpes simplex virus (HSV) encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), talimogene laherparepvec, causes regression of injected and non-injected melanoma lesions in patients and ... -
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
Ilett, E; Kottke, T; Thompson, J; Rajani, K; Zaidi, S; et al. (NATURE PUBLISHING GROUP, 2017-01-01)The anti-tumour effects associated with oncolytic virus therapy are mediated significantly through immune-mediated mechanisms, which depend both on the type of virus and the route of delivery. Here, we show that intra-tumoral ... -
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Wilkins, A; McDonald, F; Harrington, K; Melcher, A (BMC, 2019-03-06)Formenti et al. have recently reported the clinical outcomes and translational readouts of a trial of the anti-CTLA-4 inhibitor, ipilimumab, in combination with palliative radiotherapy in 39 patients with non-small cell ... -
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller, LME; Migneco, G; Scott, GB; Down, J; King, S; et al. (BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct ... -
RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma.
Smith, HG; Jamal, K; Dayal, JH; Tenev, T; Kyula-Currie, J; et al. (WILEY, 2020-06-08)Drugs that mobilise the immune system against cancer are dramatically improving care for many people. Dying cancer cells play an active role in inducing anti-tumour immunity but not every form of death can elicit an immune ... -
Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology.
Wilkins, A; Melcher, A; Somaiah, N (ELSEVIER SCIENCE LONDON, 2018-10-01) -
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin, L; Huff, AL; Kottke, T; Thompson, J; Molan, AM; et al. (AMER ASSOC CANCER RESEARCH, 2019-05-01)Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). ... -
Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.
Kottke, T; Evgin, L; Shim, KG; Rommelfanger, D; Boisgerault, N; et al. (AMER ASSOC CANCER RESEARCH, 2017-11-01)Understanding how incompletely cleared primary tumors transition from minimal residual disease (MRD) into treatment-resistant, immune-invisible recurrences has major clinical significance. We show here that this transition ... -
Synergistic antitumour effects of rapamycin and oncolytic reovirus.
Comins, C; Simpson, GR; Rogers, W; Relph, K; Harrington, K; et al. (NATURE PUBLISHING GROUP, 2018-05-01)There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer patients and one agent, Talimogene laherparepvec, has been approved for the treatment of malignant melanoma. This progress ... -
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta, M; Jennings, VA; Melcher, AA; Lise, S (FRONTIERS MEDIA SA, 2020-10-08)Cancer somatic mutations have been identified as a source of antigens that can be targeted by cancer immunotherapy. In this work, expanding on previous studies, we analyze the HLA-presentation properties of mutations that ... -
The immunological consequences of radiation-induced DNA damage.
Wilkins, AC; Patin, EC; Harrington, KJ; Melcher, AA (WILEY, 2019-04-01)Historically, our understanding of the cytotoxicity of radiation has centred on tumour cell-autonomous mechanisms of cell death. Here, tumour cell death occurs when a threshold number of radiation-induced non-reparable ... -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; et al. (CELL PRESS, 2020-03-27)Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...